• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful Use of Intravenous Immunoglobulins in an Obinutuzumab-related Acute Thrombocytopenia.

作者信息

Haage Tobias R, Surov Alexey, Mougiakakos Dimitrios, Berisha Mirjeta

机构信息

Department of Hematology and Oncology, Otto-von-Guericke University, Medical Center, Magdeburg, Germany.

Department of Radiology and Nuclear Medicine, Otto-von-Guericke University, Medical Center, Magdeburg, Germany.

出版信息

Hemasphere. 2022 Jul 15;6(8):e751. doi: 10.1097/HS9.0000000000000751. eCollection 2022 Aug.

DOI:10.1097/HS9.0000000000000751
PMID:35935607
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9351898/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ea8/9351898/afc962883569/hs9-6-e751-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ea8/9351898/88f612e73dbe/hs9-6-e751-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ea8/9351898/afc962883569/hs9-6-e751-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ea8/9351898/88f612e73dbe/hs9-6-e751-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ea8/9351898/afc962883569/hs9-6-e751-g002.jpg

相似文献

1
Successful Use of Intravenous Immunoglobulins in an Obinutuzumab-related Acute Thrombocytopenia.静脉注射免疫球蛋白在奥滨尤妥珠单抗相关急性血小板减少症中的成功应用。
Hemasphere. 2022 Jul 15;6(8):e751. doi: 10.1097/HS9.0000000000000751. eCollection 2022 Aug.
2
[Effects of intravenous immunoglobulins in thrombopenia related to septic shock].
Presse Med. 1997 Jun 14;26(20):945-50.
3
Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group.奥滨尤妥珠单抗联合苯达莫司汀治疗未经治疗滤泡淋巴瘤患者血小板减少症发生率较高：冈山海疗血液学研究组的回顾性分析。
Int J Hematol. 2022 Jun;115(6):811-815. doi: 10.1007/s12185-022-03363-3. Epub 2022 May 18.
4
Successful treatment of neonatal "autoimmune" thrombocytopenia with high-dose intravenous immunoglobulins.大剂量静脉注射免疫球蛋白成功治疗新生儿“自身免疫性”血小板减少症。
Haematologica. 1985 May-Jun;70(3):276-7.
5
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.奥妥珠单抗联合伊布替尼诱导治疗，随后采用微小残留病驱动策略治疗慢性淋巴细胞白血病患者（ICLL07 FILO）：一项单臂、多中心、2期试验。
Lancet Haematol. 2019 Sep;6(9):e470-e479. doi: 10.1016/S2352-3026(19)30113-9. Epub 2019 Jul 16.
6
[Acute thrombocytopenia after obinutuzumab administration in a patient with relapsed follicular lymphoma].[一名复发性滤泡性淋巴瘤患者使用奥妥珠单抗后出现急性血小板减少症]
Rinsho Ketsueki. 2020;61(11):1616-1619. doi: 10.11406/rinketsu.61.1616.
7
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.伊布替尼联合奥滨尤妥珠单抗与苯丁酸氮芥联合奥滨尤妥珠单抗一线治疗慢性淋巴细胞白血病（ILLUMINATE）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jan;20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3.
8
Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.波拉珠单抗维地布汀联合奥滨尤妥珠单抗和来那度胺治疗复发或难治性滤泡性淋巴瘤患者：多中心、单臂、1b/2 期研究的一个队列。
Lancet Haematol. 2021 Dec;8(12):e891-e901. doi: 10.1016/S2352-3026(21)00311-2.
9
Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.阿伐度胺联合奥滨尤妥珠单抗治疗复发或难治性B细胞非霍奇金淋巴瘤患者（CC-122-NHL-001）：一项多中心、剂量递增及扩展的1期研究。
Lancet Haematol. 2020 Sep;7(9):e649-e659. doi: 10.1016/S2352-3026(20)30208-8. Epub 2020 Aug 3.
10
A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome.在严重小儿肾病综合征中联合奥滨尤妥珠单抗和达雷妥尤单抗的全球抗 B 细胞策略。
Pediatr Nephrol. 2021 May;36(5):1175-1182. doi: 10.1007/s00467-020-04811-0. Epub 2020 Oct 28.

引用本文的文献

1
Obinutuzumab-induced severe acute thrombocytopenia: a case report and literature review.奥滨尤妥珠单抗诱导的严重急性血小板减少症：一例报告及文献综述
Front Immunol. 2025 Aug 21;16:1609862. doi: 10.3389/fimmu.2025.1609862. eCollection 2025.
2
Osteonecrosis of the Jaw Associated with Obinutuzumab in a Patient with Preceding Follicular Non-Hodgkin's Lymphoma.一名既往有滤泡性非霍奇金淋巴瘤患者使用奥妥珠单抗后发生颌骨骨坏死
J Pers Med. 2025 Apr 1;15(4):138. doi: 10.3390/jpm15040138.
3
Obinutuzumab-induced acute thrombocytopenia: a case report and literature review.

本文引用的文献

1
Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer.血小板 PD-L1 反映了肿瘤内 PD-L1 的集体表达，并预测了非小细胞肺癌的免疫治疗反应。
Nat Commun. 2021 Dec 1;12(1):7005. doi: 10.1038/s41467-021-27303-7.
2
[Acute thrombocytopenia after obinutuzumab administration in a patient with relapsed follicular lymphoma].[一名复发性滤泡性淋巴瘤患者使用奥妥珠单抗后出现急性血小板减少症]
Rinsho Ketsueki. 2020;61(11):1616-1619. doi: 10.11406/rinketsu.61.1616.
3
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
奥滨尤妥珠单抗诱导的急性血小板减少症：一例病例报告及文献综述
Front Oncol. 2024 Dec 17;14:1509567. doi: 10.3389/fonc.2024.1509567. eCollection 2024.
4
Acute Thrombocytopenia Complicating the Initial Administration of Obinutuzumab: Is It More Frequent Than We Think?奥滨尤妥珠单抗初始给药并发急性血小板减少症：是否比我们想象的更常见？
Oncol Ther. 2024 Mar;12(1):157-161. doi: 10.1007/s40487-023-00259-y. Epub 2024 Jan 22.
在 GALLIUM 研究中，奥滨尤妥珠单抗或利妥昔单抗联合化疗治疗初治滤泡性淋巴瘤：化疗对疗效和安全性的影响。
J Clin Oncol. 2018 Aug 10;36(23):2395-2404. doi: 10.1200/JCO.2017.76.8960. Epub 2018 Jun 1.
4
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.奥滨尤妥珠单抗用于滤泡性淋巴瘤的一线治疗。
N Engl J Med. 2017 Oct 5;377(14):1331-1344. doi: 10.1056/NEJMoa1614598.
5
Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.接受奥滨尤妥珠单抗治疗的慢性淋巴细胞白血病患者的细胞因子释放及其与输注相关反应的可能关系。
Blood. 2015 Dec 10;126(24):2646-9. doi: 10.1182/blood-2015-09-670802. Epub 2015 Oct 7.
6
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.奥滨尤妥珠单抗联合苯丁酸氮芥治疗伴有合并症的 CLL 患者。
N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8.
7
Rituximab-induced acute severe thrombocytopenia: a case series in patients with mantle cell lymphoma.利妥昔单抗诱导的急性严重血小板减少症：套细胞淋巴瘤患者的病例系列
Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):602-5. doi: 10.1016/j.clml.2013.04.013. Epub 2013 Jul 17.
8
Rituximab-induced thrombocytopenia: a cohort study.利妥昔单抗诱导的血小板减少症：一项队列研究。
Eur J Haematol. 2012 Sep;89(3):256-66. doi: 10.1111/j.1600-0609.2012.01808.x. Epub 2012 Jul 5.
9
Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon.利妥昔单抗相关的急性血小板减少症：一种诊断不足的现象。
Am J Hematol. 2009 Apr;84(4):247-50. doi: 10.1002/ajh.21372.
10
Rituximab-induced acute thrombocytopenia: a case report and review of the literature.利妥昔单抗诱导的急性血小板减少症：一例病例报告及文献综述
Med Oncol. 2009;26(1):45-8. doi: 10.1007/s12032-008-9079-6. Epub 2008 Jun 10.